| A | B | C | |
|---|---|---|---|
| 1 | Drugs | ||
| 2 | Brand | fka RG7412, MABT5102A | |
| 3 | Generic | crenezumab | |
| 4 | Company | Roche | |
| 5 | MOA | IgG4 aggregated Abeta, 10x higher affinity for soluble oligomers at AA16-24 | |
| 6 | Potential cross-reactivity in human plasma |
| A | B | C | |
|---|---|---|---|
| 1 | Drugs | ||
| 2 | Brand | fka RG7412, MABT5102A | |
| 3 | Generic | crenezumab | |
| 4 | Company | Roche | |
| 5 | MOA | IgG4 aggregated Abeta, 10x higher affinity for soluble oligomers at AA16-24 | |
| 6 | Potential cross-reactivity in human plasma |
Martin Shkreli